Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Go back to Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.75 -1.25 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.00 | 52 Week High | $118.49 | |||
| Open | $126.46 | 52 Week Low | $55.00 | |||
| Day High | $128.08 | P/E | N/A | |||
| Day Low | $126.04 | EPS | $-0.56 | |||
| Volume | 1,035,974 | |||||
| Morgan Stanley Capital Protected Notes for S&P 500 Index (NASDAQ: MOR) | Delayed: 18.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.96 | 52 Week High | $13.71 | |||
| Open | $18.96 | 52 Week Low | $9.64 | |||
| Day High | $18.96 | P/E | N/A | |||
| Day Low | $18.96 | EPS | $0.00 | |||
| Volume | 1,914,813 | |||||
